Beijing Konruns Pharmaceutical Co.,Ltd.

Shanghai Stock Exchange 603590.SS

Beijing Konruns Pharmaceutical Co.,Ltd. EBITDA Margin for the year ending December 31, 2023: 18.27%

Beijing Konruns Pharmaceutical Co.,Ltd. EBITDA Margin is 18.27% for the year ending December 31, 2023, a -16.65% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Beijing Konruns Pharmaceutical Co.,Ltd. EBITDA Margin for the year ending December 31, 2022 was 21.92%, a -21.50% change year over year.
Beijing Konruns Pharmaceutical Co.,Ltd. EBITDA Margin for the year ending December 31, 2021 was 27.92%, a -5.47% change year over year.
Beijing Konruns Pharmaceutical Co.,Ltd. EBITDA Margin for the year ending December 31, 2020 was 29.54%, a 31.06% change year over year.
Beijing Konruns Pharmaceutical Co.,Ltd. EBITDA Margin for the year ending December 31, 2019 was 22.54%, a -31.19% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Shanghai Stock Exchange: 603590.SS

Beijing Konruns Pharmaceutical Co.,Ltd.

CEO	Ms. Yuping Sun
IPO Date	Sept. 3, 2018
Location	China
Headquarters	Building 3
Employees	447
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research, production, and sale of various drugs in China. The company offers Su Ling product in the hemagglutinin preparation market used to reduce bleeding during surgery and control postoperative surgery. It also engages in the development of drug candidates, including CX1026, CX1003, and KC1036. The company was founded in 2003 and is headquartered in Beijing, China.

Key trends

Past 5 years